- Home
- RFIL vs ENLV Comparison
RFIL vs ENLV Comparison
Compare RFIL & ENLV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | RFIL | ENLV |
|---|---|---|
| Founded | 1979 | 2005 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Electrical Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 191.3M | 196.2M |
| IPO Year | 1996 | 2014 |
Fundamental Metrics
Financial Performance| Metric | RFIL | ENLV |
|---|---|---|
| Price | $18.57 | $0.72 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 1 | 2 |
| Target Price | $11.25 | ★ $20.00 |
| AVG Volume (30 Days) | 229.1K | ★ 412.5K |
| Earning Date | 06-15-2026 | 05-29-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 101.59 | N/A |
| EPS | N/A | N/A |
| Revenue | ★ $55,325,000.00 | N/A |
| Revenue This Year | $9.65 | N/A |
| Revenue Next Year | $6.40 | N/A |
| P/E Ratio | $1,203.00 | ★ N/A |
| Revenue Growth | ★ 10.22 | N/A |
| 52 Week Low | $4.08 | $0.66 |
| 52 Week High | $19.77 | $2.10 |
Technical Indicators
Market Signals| Indicator | RFIL | ENLV |
|---|---|---|
| Relative Strength Index (RSI) | 58.26 | 38.91 |
| Support Level | $6.31 | $0.66 |
| Resistance Level | $19.39 | $1.23 |
| Average True Range (ATR) | 1.45 | 0.07 |
| MACD | -0.25 | -0.01 |
| Stochastic Oscillator | 72.91 | 11.66 |
Price Performance
Historical ComparisonAbout RFIL RF Industries Ltd.
RF Industries Ltd is engaged in the design, manufacture, and marketing of interconnect products and systems, including coaxial and specialty cables, fiber optic cables and connectors, and electrical and electronic specialty cables. The company has one operating segment. The company operates in Canada, Germany, China, the USA, and the United Kingdom, and Others.
About ENLV Enlivex Therapeutics Ltd.
Enlivex Ltd is a clinical stage macrophage reprogramming immunotherapy company currently focused on the late-stage clinical development of Allocetra, a novel therapy designed to treat the joint disease osteoarthritis. Additionally, it has developed a treasury using the RAIN protocol, which currently serves as the primary treasury reserve asset of the company.